Cargando…
Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives
Up to 50% of patients with uveal melanoma develop metastatic disease with poor prognosis. Regional, mainly liver-directed, therapies may induce limited tumor responses but do not improve overall survival. Response rates of metastatic uveal melanoma (MUM) to systemic chemotherapy are poor. Insights i...
Autores principales: | Buder, Kristina, Gesierich, Anja, Gelbrich, Götz, Goebeler, Matthias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Science Inc
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892799/ https://www.ncbi.nlm.nih.gov/pubmed/24403233 http://dx.doi.org/10.1002/cam4.133 |
Ejemplares similares
-
Anti‐PD‐1 antibodies in metastatic uveal melanoma: a treatment option?
por: Bender, Carolin, et al.
Publicado: (2017) -
Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma
por: Hassel, Jessica C., et al.
Publicado: (2017) -
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
por: Najjar, Yana G, et al.
Publicado: (2020) -
Early detection of metastatic uveal melanoma by the analysis of tumor‐specific mutations in cell‐free plasma DNA
por: Le Guin, Claudia H. D., et al.
Publicado: (2021) -
Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors
por: Sander, Michael S., et al.
Publicado: (2021)